Akari shareholders approve share sub-division, warrant exercise, and new articles

Akari Therapeutics Plc

Approved exercisability of warrants issued in October 2025 offering under Nasdaq Listing Rule 5635(d).
Approved sub-division and re-designation of ordinary shares into 1 ordinary share (0.000000005 GBP) and 19,999 deferred shares.
Authorised directors to allot shares up to nominal amount of USD 3,000, expiring June 30, 2030.
Approved a share buyback contract for all deferred shares and adoption of new articles of association.
Special resolution passed to allot equity securities for cash without pre-emption rights, effective for five years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.